CA
FTXH icon

Continuum Advisory’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Continuum Advisory’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-650
Closed -$17.5K – 1778
2024
Q4 		$17.5K Hold
650
– – ﹤0.01% 876
2024
Q3 		$18.2K Hold
650
– – ﹤0.01% 870
2024
Q2 		$17.7K Hold
650
– – ﹤0.01% 813
2024
Q1 		$17.5K Buy
+650
New +$17.9K ﹤0.01% 806

Other funds holding FTXH

LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
WFA
WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return
VCM
Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Continuum Advisory's FTXH Position: Q1 2025 in Review

Continuum Advisory sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q1 2025, closing a stake of 650 shares — an estimated $17.5K sold.

Continuum Advisory first reported a position in FTXH in Q1 2024 and held it in 4 quarters. The position peaked at $18.2K in Q3 2024. 20 funds tracked by Wall St. Rank hold FTXH as of Q1 2025.

  • Continuum Advisory reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 650 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2025, an estimated $17.5K.
  • Continuum Advisory first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2024 and held it in 4 quarters.
  • Continuum Advisory's First Trust Nasdaq Pharmaceuticals ETF position peaked at $18.2K in Q3 2024.
  • 20 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.